NSE: GLENMARK | BSE: 532296

Strong Performer, Getting Expensive

Download real time

2078.00 -7.20 (-0.35%)

62.92% Gain from 52W Low

72,609 NSE+BSE Volume

NSE 22 Sep, 2025 10:08 AM (IST)

58,641.3

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

12 Feb 2018

2078.00

-0.35%

Result Review of Glenmark Pharmaceuticals

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

IDBI Capital

Q3FY18 revenues reduced by 13.1% YoY and 2.3% QoQ, above our forecast by 2.3%. EBITDA margin of 14.6% were lower than our estimates of 19.4%, mainly on the back of continuing pain in the US market and higher other expenses. PAT of Rs935mn, -79.7% YoY and -54.3% was taking into account writebacks and deferred tax asset which is applicable in all companies. Given the continuous pain in the US market, plus challenging environment with competition in gMupirocin, higher base business erosion and muted growth trajectory, we have revised downwards our sales/EBITDA/EPS estimates by...

Glenmark Pharmaceuticals Ltd. has gained 26.96% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

12 Feb 2018

2078.00

-0.35%

Glenmark

Buy: Glenmark Pharmaceuticals Ltd.

Dolat Capital

Beyond gZetia . Budding niche product pipeline Ex US overall revenue growth was at 16% YoY and is expected to grow over 15% YoY going forward. The management has guided for better gross...

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

07 Nov 2017

2078.00

-0.35%

Result Review of Glenmark Pharmaceuticals

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

IDBI Capital

Q2FY18 revenues increased by 1.5% YoY lower than our forecast by 5.6%. EBITDA margin of 17.4% were lower than our estimates of 19.7%, mainly on the back of sales mix and higher expenses. PAT of Rs2bn, -8.6% YoY, was lower by 19.6%. For FY18, Glenmark has guided for the US business to have a run-rate of USD125mn+, however, with overall EBITDA margins of 21-22%. We are confident of Glenmark signing one out-licensing deal to help reduce debt. Key Highlights and Investment Rationale Pain continues for the US franchise...

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.

Glenmark Pharmaceuticals Ltd.

06 Nov 2017

2078.00

-0.35%

Glenmark Pharma - 2QFY18 Result Update

Buy: Glenmark Pharmaceuticals Ltd.

Target

Reliance Securities

ff FY18 Guidance: The Management expects sales (including gZetia) to grow by 6% YoY, while pegging EBITDA margin and gross margin at 21-22% and 68%, respectively. R&D; spend is pegged at 11-13% of sales. GNP plans to launch Ceylon Pharma's product (SalmaxgAdvair/...

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

04 Nov 2017

2078.00

-0.35%

Glenmark (2QFY18): Debt key to re-rating. Maintain BUY

Buy: Glenmark Pharmaceuticals Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 1,000 (18x Sep-19E and Rs 135/sh for innovative pipeline). Glenmarks (GNP) 2QFY18 performance was slightly below expectations. The overall top-line grew 2% YoY to Rs 22.2bn. While a sequential decline in the US was expected on account of the loss of exclusivity of gZetia, US$113mn for the quarter was below our expectations. The EBITDA margin came in at 16%. There were one-time bonuses of Rs 1.1bn paid during the quarter, adjusted for which the margin would have been 21% and ~100bps ahead of our estimates. PAT was ~Rs 2bn, down ~9% YoY.

Glenmark Pharmaceuticals Ltd. has gained 37.18% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

03 Nov 2017

2078.00

-0.35%

Glenmark Pharma: US growth to pick up; high debt remains an overhang

Neutral: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

growth to pick up; high debt remains an overhang Net sales increased marginally by ~2% YoY (-5% QoQ) to INR22.2b (4% miss). EBITDA declined ~11% YoY to INR3.6b (2% beat), with the margin coming in at 16% (-230bp YoY, -740bp QoQ). Employee expenses included annual employee bonus of ~INR1.1b in 2Q. Adjusted for this, EBITDA came in below the previous quarter's level (note that 1QFY18 included Zetia sales with >80% GM). According to management, the improvement in margins...

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

03 Nov 2017

2078.00

-0.35%

Glenmark

Hold: Glenmark Pharmaceuticals Ltd.

Sharekhan

The management gave a cautious outlook, as there is significant pricing pressure on the US base business owing to consolidation of players and increasing competition, which will continue for next two years. Although there are few more significant opportunities that will emerge in FY18 and FY19, we feel that a few overhangs will continue in the near term: 1) pricing pressure in the...

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

03 Nov 2017

2078.00

-0.35%